Belbuca is a prescription pain-relief film containing buprenorphine that you place inside your cheek, where it dissolves and delivers medication through the lining of your mouth. It’s FDA-approved for managing chronic pain that’s severe enough to need around-the-clock opioid treatment, specifically when other pain management options haven’t worked well enough. Unlike pills or patches, this thin film absorbs directly through the cheek tissue, which changes how the drug enters your bloodstream and how your body processes it.
How It Works
Buprenorphine, the active ingredient in Belbuca, is a partial opioid. That means it activates the brain’s pain-relief receptors, but only partially, producing a ceiling effect where pain relief plateaus even at higher doses. This makes it behave differently from full opioids like oxycodone or morphine. It also blocks another type of opioid receptor involved in mood, which may contribute to its overall pain-management profile.
Because it’s a partial activator rather than a full one, buprenorphine carries a somewhat lower risk of the dangerous breathing suppression that makes full opioids so risky at high doses. That said, it’s still classified as a Schedule III controlled substance in the United States, meaning it has recognized potential for misuse, dependence, and withdrawal.
How to Apply the Film
Belbuca is applied every 12 hours. Before placing the film, you wet the inside of your cheek, either with your tongue or by rinsing with water. Then you open the sealed packet and immediately press the yellow side of the film against the wet cheek lining, holding it with clean, dry fingers for about five seconds.
Once placed, leave the film alone. Don’t poke at it with your tongue or fingers, and avoid eating or drinking until it fully dissolves, which typically takes about 30 minutes. If you chew or swallow the film instead of letting it dissolve against your cheek, your body absorbs significantly less of the medication, making it less effective.
Common Side Effects
Nausea is by far the most frequently reported side effect. In clinical trials, it affected up to 50% of patients who had never taken opioids before during the initial dose-adjustment phase, though it dropped to around 10% once patients settled into a stable dose. For people who had previously used other opioids, nausea during the adjustment phase was lower, around 17%.
Other side effects reported in more than 5% of patients include:
- Constipation (8 to 13% during dose adjustment)
- Vomiting (7 to 8%)
- Headache (7 to 8%)
- Dizziness (5 to 6%)
- Drowsiness (5 to 7%)
- Fatigue (around 5%)
Most of these side effects are more common during the first weeks when the dose is being gradually increased, and they tend to ease once your body adjusts. Dry mouth, diarrhea, and upper respiratory infections were also reported at lower rates.
Dental Health Warning
In 2022, the FDA issued a safety warning about dental problems linked to buprenorphine products that dissolve in the mouth, including Belbuca. Reports of tooth decay, cavities, oral infections, and even tooth loss came in from patients who had no prior dental issues. The concern is that the medication changes the environment inside the mouth in ways that promote decay over time.
If you’re prescribed Belbuca, take a few protective steps each time you use it. After the film has fully dissolved, take a large sip of water, gently swish it around your teeth and gums, and swallow. Wait at least one hour before brushing your teeth, because brushing too soon can damage enamel while your mouth’s chemistry is still off balance. You should also schedule a dental visit soon after starting the medication, let your dentist know you’re using a buccal buprenorphine product, and keep up with regular dental checkups. Your dentist can create a preventive plan tailored to the added decay risk.
Who It’s Prescribed For
Belbuca is specifically intended for chronic pain that requires continuous, daily opioid management. It’s not designed for occasional or short-term pain, like post-surgical recovery or a flare-up. The FDA indication makes clear that it’s reserved for situations where other treatments, including non-opioid options, haven’t provided adequate relief.
In clinical trials, Belbuca was studied separately in two patient groups. People who had never taken opioids (“opioid-naive”) were started on lower doses, ranging from 75 to 450 micrograms. People who were already taking opioids for pain (“opioid-experienced”) were started on higher doses, from 150 to 900 micrograms. This distinction matters because your body’s tolerance to opioids determines how much buprenorphine you need and how your treatment is adjusted over time. One notable finding from trials: patients on placebo who had previously used opioids experienced drug withdrawal symptoms at a rate of 10%, compared to only 3% of those who continued on Belbuca, highlighting the physical dependence that comes with long-term opioid use.
How Belbuca Differs From Other Buprenorphine Products
Buprenorphine has been available in the U.S. since 1981, but it comes in several different forms for different purposes. Suboxone and similar sublingual (under-the-tongue) products are used to treat opioid use disorder. Belbuca is distinct: it’s prescribed purely for chronic pain management, not for addiction treatment, and it uses a buccal (inside-the-cheek) delivery route.
The buccal film format offers more consistent absorption than swallowing a pill, since the drug bypasses the digestive system and enters the bloodstream directly through the cheek lining. This also means the medication works at lower doses than an oral tablet would require. The tradeoff is that proper placement matters. If you don’t follow the application steps correctly, you may not get the intended dose, which can affect pain control and potentially trigger withdrawal symptoms in opioid-dependent patients.